XTL Biopharmaceuticals Ltd
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company L… Read more
XTL Biopharmaceuticals Ltd (XTLB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2017: -0.083x
Based on the latest financial reports, XTL Biopharmaceuticals Ltd (XTLB) has a cash flow conversion efficiency ratio of -0.083x as of December 2017.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-301.00K) by net assets (ILA3.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
XTL Biopharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how XTL Biopharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
XTL Biopharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of XTL Biopharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kyntra Bio, Inc.
NASDAQ:KYNB
|
-0.106x |
|
Eden Empire Inc
PINK:EDNEF
|
0.049x |
|
CYBERAGENT (CL2.SG)
STU:CL2
|
N/A |
|
OLYMPUS - Dusseldorf Stock Exchang
DU:OLY1
|
0.079x |
|
BENETEAU (3GD.SG)
STU:3GD
|
N/A |
|
Broadcom (AVGO) BMO Canadian Depositary Receipt (CAD Hedged)
NEO:ZAVG
|
N/A |
|
J4 Ventures Inc.
V:JJJJ-P
|
-0.310x |
|
PEAB4F
SA:PEAB4F
|
N/A |
Annual Cash Flow Conversion Efficiency for XTL Biopharmaceuticals Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of XTL Biopharmaceuticals Ltd from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA5.43 Million | ILA-1.62 Million | -0.298x | +6.52% |
| 2023-12-31 | ILA2.22 Million | ILA-707.00K | -0.318x | -41.35% |
| 2022-12-31 | ILA4.00 Million | ILA-901.00K | -0.225x | -14.54% |
| 2021-12-31 | ILA5.33 Million | ILA-1.05 Million | -0.197x | -44.61% |
| 2020-12-31 | ILA6.25 Million | ILA-850.00K | -0.136x | -4.56% |
| 2019-12-31 | ILA6.98 Million | ILA-908.00K | -0.130x | -32.67% |
| 2018-12-31 | ILA8.32 Million | ILA-816.00K | -0.098x | +68.46% |
| 2017-12-31 | ILA3.62 Million | ILA-1.12 Million | -0.311x | +51.77% |
| 2016-12-31 | ILA2.69 Million | ILA-1.73 Million | -0.645x | -69.27% |
| 2015-12-31 | ILA4.89 Million | ILA-1.86 Million | -0.381x | +27.86% |
| 2014-12-31 | ILA4.68 Million | ILA-2.47 Million | -0.528x | -43.33% |
| 2013-12-31 | ILA6.79 Million | ILA-2.50 Million | -0.368x | -- |